Ketryx, an AI-native compliance platform for safety-critical product development, announced record momentum as it enters 2026, driven by surging demand for validated AI. The company now serves four of the top five Fortune 500 MedTech companies, and its platform supports products reaching more than 100 million patients worldwide. This achievement underscores a shift in the medical device, digital health, diagnostics, and life sciences sectors from AI experimentation to enterprise-wide deployment.
According to the announcement, Ketryx has proven that safety-critical product development no longer has to be slow. The platform automates documentation, creates traceability, and accelerates release cycles without disrupting existing workflows. Its AI Agents are reported to cut manual work by 90 percent and close compliance gaps, elevating both speed and quality across the product lifecycle.
As organizations in regulated industries adopt AI at scale, the need for validated systems that ensure compliance with standards such as FDA regulations and ISO 13485 becomes critical. Ketryx's momentum reflects a broader industry trend toward integrating AI not just for innovation but for compliance and efficiency. The company's ability to serve four of the top five MedTech firms positions it as a key player in the evolving landscape of AI-driven quality management.
For more information about Ketryx and its platform, visit www.ketryx.com.
